Exploring the relationship between urinary phthalate metabolites and Crohns disease via oxidative stress, and the potential moderating role of gut microbiota: A conditional mediation model
Disclosures: Muhammad Atif Zahoor: Nothing to Disclose, Nahla Fadlelmawla: Nothing to Disclose, Adrian Kuipery: Nothing to Disclose, Joshua Feld: Nothing to Disclose, Alexander Mosa: Nothing to Disclose, Adam Gehring: Nothing to Disclose, Jordan Feld: Mirum: Consultant, AbbVie, Bluejays, Gilead, Janssen, GSK, Roche, VIR Roche: Consultant, Bluejays: Consultant, Gilead: Consultant, Janssen: Consultant, GSK: Consultant, Roche: Consultant, VIR Biotechnology: Consultant, Altimmune, AbbVie, Gilead, Jannsen, GSK, Roche, VIR Bio: Grant/Research Support 383 TENOFOVIR ALAFENAMIDE FUMARATE IN TREATMENT-NAVE CHRONIC HEPATITIS B PATIENTS WITH LIVER FIBROSIS: A PRELIMINARY NON-INVASIVE RESULTS OF 96 WEEKS Jialing Zhou 1 Xiaoning Wu 1 chuanwu zhu 2 Jiming Zhang 3 Ping Li 4 Tao Han 5 huiguo ding 6 Chenghai Liu 7 Wen Xie 8 Qing Xie 9 Yali Zong 10 Hong You 11 Jidong Jia 12 , 1 Beijing Friendship hospital, Capital medicine university, 2 The Fifth Peoples Hospital of Suzhou, China, 3 Huashan Hospital, Shanghai Medical College, Fudan University, China, 4 Tianjin Second Peoples Hospital, China, 5 Tianjin Medical University, Tianjin Union Medical Center, 6 Beijing Youan Hospital, Capital Medical University, China, 7 Shanghai Traditional Chinese Medicine Hospital, 8 Beijing Ditan Hospital, Capital Medical University, Beijing, China, 9 Ruijin Hospital, 10 The Ninth Hospital of Nanchang, China, 11 Capital Medical University, 12 Beijing Friendship Hospital, Capital Medical University, China Background: To investigate the antifibrotic efficacy and safety of tenofovir alafenamide (TAF) in treatment-nave chronic hepatitis B (CHB) with liver fibrosis
Metabolism 119:154767
FEMS Yeast Res 5:12151228
